Plasma glutathione as a risk marker for the severity and functional outcome of acute atherothrombotic and cardioembolic stroke

Table 1 General characteristics of patients

Variables	Cerebral microangiopathy	LA	CE	p**
N	31	43	36
Age, years	69 [60; 75]	62 [55; 66]^#	68 [60; 75]	0.01
Sex, % man	39	79*	39	0.00014
Chronic cerebral ischemia	31 [100%]	11 [25.6%]*	18 [50.0%]*	0.025
NIHSS on admission	–	9 [5; 12]	12 [7; 13]
NIHSS > 10, n	–	19 (44.2%)	19 (52.8%)
mRs (21st day)	–	3 [1; 4]	3 [2; 4]
mRs > 2, n	–	24 (55.8%)	21 (58.3%)
BI (21st day)	–	60 [45; 86]	75 [30; 85]
BI < 61, n	–	22 (51.1%)	19 (52.8%)
tGSH, μM	3.1 [2.1; 3.7]	1.6 [1.1; 2.7]^#	1.1 [0.8; 2.2]^##	0.00001
total cysteine, μM	267 [230; 322]	325 [287; 363]	172 [135; 336]^&&	0.00009
total homocysteine, μM	13.0 [11.4; 15.9]	14.4 [12.2; 19.8]	8.7 [5.3; 14.1]^&	0.0017
rGSH, nM	240 [180; 370]	42 [25; 68]^##	39 [25; 57] ^##	< 0.00001

All values represented as median [Q1; Q3]
BI Bartel index, mRs modified Rankin scale, NIHSS National Institutes of Health Stroke Scale, rGSH reduced glutathione, tGSH total glutathione
*p < 0.05 (binomial test)
**Tamhane test for all groups
^#Tamhane test p < 0.05, ^##p < 0.005 compared to cerebral microangiopathy group
^&Tamhane test p < 0.05, ^&&p < 0.001 compared to LA group